Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Research & Development (2016 - 2025)

China Pharma Holdings' Research & Development history spans 13 years, with the latest figure at $190041.0 for Q4 2025.

  • For Q4 2025, Research & Development rose 34642.41% year-over-year to $190041.0; the TTM value through Dec 2025 reached $280901.0, down 1.07%, while the annual FY2025 figure was $280901.0, 1.07% down from the prior year.
  • Research & Development reached $190041.0 in Q4 2025 per CPHI's latest filing, up from $40321.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $190086.0 in Q1 2021 to a low of $547.0 in Q4 2024.
  • Average Research & Development over 5 years is $65487.2, with a median of $43047.0 recorded in 2023.
  • Peak YoY movement for Research & Development: crashed 99.63% in 2024, then skyrocketed 34642.41% in 2025.
  • A 5-year view of Research & Development shows it stood at $54048.0 in 2021, then plummeted by 48.2% to $27999.0 in 2022, then surged by 426.99% to $147552.0 in 2023, then plummeted by 99.63% to $547.0 in 2024, then surged by 34642.41% to $190041.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Research & Development are $190041.0 (Q4 2025), $40321.0 (Q3 2025), and $20952.0 (Q2 2025).